NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Pablo Mandó
Instituto Universitario CEMIC - Buenos Aires / Argentina
Others
AD Scientific Index ID: 5895608
CEMIC University Institute
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Pablo Mandó's MOST POPULAR ARTICLES
1-)
Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patientsEP Juliá, P Mandó, MM Rizzo, GR Cueto, F Tsou, R Luca, C Pupareli, ...Cancer Immunology, Immunotherapy 68, 1585-1596, 2019432019
2-)
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy eraP Mandó, SG Rivero, MM Rizzo, M Pinkasz, EM LevyThe Breast 60, 15-25, 2021422021
3-)
Breast cancer in young women presents with more aggressive pathologic characteristics: Retrospective Analysis From an Argentine National DatabaseV Fabiano, P Mandó, M Rizzo, C Ponce, F Coló, M Loza, J Loza, M Amat, ...JCO global oncology 6, 639-646, 2020382020
4-)
Efficacy and safety of nivolumab in previously treated patients with non–small-cell lung cancer: real world experience in ArgentinaC Martin, L Lupinacci, F Perazzo, C Bas, O Carranza, C Puparelli, ...Clinical Lung Cancer 21 (5), e380-e387, 2020242020
5-)
High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patientsP Mandó, M Rizzo, MP Roberti, EP Juliá, MB Pampena, ...OncoTargets and therapy, 2901-2910, 2018192018
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept